In contrast, higher MXD3 expression was associated with clinical benefits in bladder cancer patients to PD-L1 ICB and hence exhibited higher survival durations than bladder cancer cohorts that had lower MXD3 expression levels. Here, CD274 is linked to urinary bladder cancer.